Monitor for any Form 4 filings indicating Armistice has exercised the options. If/when exercise occurs, expect substantial selling pressure as the holder can sell shares at a profit. The low exercise price relative to market suggests imminent exercise.
INM drugs
INM drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 19 $1.60entry
- T+1 · 6mo ago +0.63%α −0.41% · $1.61
- T+5 · 6mo ago +3.75%α +1.45% · $1.66
- T+20 · 5mo ago −6.88%α −7.86% · $1.49
- T+60 · 3mo ago −10.63%α −16.92% · $1.43
Price Chart
How similar events traded
Executive Summary
InMed Pharmaceuticals amended preferred investment options held by Armistice Capital, reducing the exercise price from $16.60 to $0.80. This drastically increases the likelihood of exercise, which would bring significant dilution to existing shareholders. The move signals financial distress at the micro-cap company.
Key Facts
- Exercise price on 278,761 preferred investment option shares reduced from $16.60 to $0.80.
- Amendment entered into on May 18, 2026 with Armistice Capital Master Fund Ltd.
- Total potential dilution of up to 278,761 common shares if fully exercised.
- No new cash raised through this amendment.
- Company market cap is approximately $2M, making dilution material.
Financial Impact
Potential dilution of up to 278,761 shares or roughly doubling the current share count based on market cap.
Risk Factors
- Massive dilution to existing shareholders upon exercise.
- Potential near-term stock price decline from overhang of exercisable shares.
- Indication of financial distress and need for future capital.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001062993-26-002787 |
| Exhibit: exhibit99-1.htm | 0001062993-26-002787 |
| Document: form8k.htm | 0001062993-26-002787 |
| Document: 0001062993-26-002787-index-headers.html | 0001062993-26-002787 |
| Document: 0001062993-26-002787-index.html | 0001062993-26-002787 |
| Document: 0001062993-26-002787.txt | 0001062993-26-002787 |
Track record
22 reports on INM
5 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +24.51% at T+1 after the Nov 3, 2026 report. 9 of 11 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $16.00 Now $19.87 +24.19% settles Dec 8
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
- Nov 3, 202613d ago 8-K Bearish 6/10 Entry $1.75 Now $19.87 −1035.43% settles Dec 3
- Nov 2, 202614d ago 425 Neutral 3/10 Entry $1.68 Now $19.87 +1082.74% settles Dec 2
- Oct 26, 202621d ago 425 Neutral 3/10 Entry $1.59 Now $19.87 +1149.69% settles Nov 24
- Oct 7, 20265w ago SC 13G/A Bullish 5/10 Entry $1.33 to $1.32 Now $19.87 +1393.99% ▼ −0.68% +4.61% vs SPY
- Oct 2, 20266w ago EFFECT Neutral 3/10 Entry $1.33 to $1.60 Now $19.87 +1393.99% ▲ +20.30% +22.11% vs SPY
- Sep 18, 20268w ago 8-K Bearish 6/10 Entry $1.38 to $1.37 Now $19.87 −1339.86% ▲ +1.06% +0.15% vs SPY
- Sep 9, 20269w ago 425 Neutral 6/10 Entry $1.31 to $1.33 Now $19.87 +1416.79% ▲ +1.53% −0.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers